Molecular Archives - Page 8 of 10

02Feb

Biocartis announces CE-IVD marking of its Idylla™ MSI Test

Products are for professional/laboratory use only.

Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the CE-IVD marking of its fully automated Idylla™ MSI Test which allows for fast and accurate information on a patient’s MSI status directly from a single sample of FFPE ^[1] colorectal cancer tumor tissue. This CE-IVD launch is a key addition to Biocartis’ colorectal cancer (CRC) Idylla™ test menu as MSI detection is currently recommended for all patients with CRC ^[2].

biocartis, CE-IVD, idylla, msi

22Jun

Molecular

ZytoVision FISH Probes for Lung Cancer

Products are for professional/laboratory use only.

ZytoVision’s ZytoLight® products are designed for the identification of genetic aberrations eg. translocations, deletions, amplifications and chromosomal aneuploidies by Fluorescence in situ Hybridisation (FISH) in formalin-fixed, paraffin-embedded tissue sections, cell samples, blood or bone marrow smears and metaphase chromosome spreads.

FISH, FISH Probes, lung cancer, zytolight, zytovision

23Apr

Haematology, Molecular

Invivoscribe LymphoTrack Dx IVD Assays now available

Products are for professional/laboratory use only. Abacus dx is pleased to inform you that the Invivoscribe LymphoTrack Dx IVD Assays are now available.

invivoscribe, Ion pgm, lymphotrack dx, miseq, registered, TGA

25Jan

Molecular

Asuragen: FragileX

Products are for professional/laboratory use only.

The AmplideX^® suite of products is designed to solve unmet testing needs in inherited genetic disorders. The technology overcame a 20-year challenge by reliably amplifying the FMR1 gene. This allowed researchers to gain a deeper understanding of fragile X syndrome, the most common known inherited cause of intellectual disability and autism.

amplidex, asuragen, FMR1, FragileX

25Jan

Molecular

Asuragen: C9orf72

Products are for professional/laboratory use only.

The AmplideX® C9orf72 Kit is a tool for the reliable amplification of the hexanucleotide CG repeat in the C9orf72 gene associated with amyotrophic lateral sclerosis and frontotemporal dementia.

amplidex, asuragen, c9orf72

03Feb

Molecular

Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods

Products are for professional/laboratory use only.

Press Release: Mechelen, Belgium, 27 June 2018

biocartis, braf, cancer, EGFR, idylla, KRAS, next generation sequencing, NGS, nras, tumour

03Feb

Molecular

Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy

Products are for professional/laboratory use only.

PRESS RELEASE: 28 August 2018

Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer¹ (mCRC).

biocartis, colorectal cancer, ectodomain mutations, EGFR, idylla, liquid biopsy, oncology

03Feb

Molecular

Asuragen announce the launch of AmplideX PCR/CE DMPK Kit for myotonic dystrophy

Products are for professional/laboratory use only.

Abacus dx would like to update you with the latest products from Asuragen.

amplidex, asuragen, CTG, dm1, DMPK, gene, myotonic dystrophy type 1

03Feb

Molecular

Study Demonstrates Ability of Idylla EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

Products are for professional/laboratory use only.

A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).

biocartis, EGFR, idylla, lung cancer, next generation sequencing, NGS

Top